Cargando…
YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation
BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is an aggressive cancer with exceedingly poor prognosis, and chemoresistance is a huge challenge for treatment. N6‐methyladenosine (m(6)A) modification plays an important role in the progression and chemoresistance of cancers. We aimed to investigate...
Autores principales: | Huang, Chen‐Song, Zhu, Ying‐Qin, Xu, Qiong‐Cong, Chen, Siyun, Huang, Yue, Zhao, Guangyin, Ni, Xuhao, Liu, Bo, Zhao, Wei, Yin, Xiao‐Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9191870/ https://www.ncbi.nlm.nih.gov/pubmed/35696608 http://dx.doi.org/10.1002/ctm2.848 |
Ejemplares similares
-
METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m(6)A-YTHDF2-dependent manner
por: Xu, Qiong-Cong, et al.
Publicado: (2022) -
YTHDF1 promotes mRNA degradation via YTHDF1‐AGO2 interaction and phase separation
por: Li, Jiong, et al.
Publicado: (2021) -
Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma
por: Chen, Hua-Dong, et al.
Publicado: (2020) -
Regulation of glucose and glutamine metabolism to overcome cisplatin resistance in intrahepatic cholangiocarcinoma
por: Yang, So Mi, et al.
Publicado: (2023) -
Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma
por: Chen, Xing, et al.
Publicado: (2022)